Indaptus Therapeutics, Inc. (INDP) stock continued to soar in the pre-market today after rising to certain heights in the previous trade. INDP stock price saw a surge of 32.47% $14.24 a share at the time of this writing. The stock went high by 52.05% bringing per share price $10.75 at the previous closing. The stock soared after it received notice of allowance for a strategic patent. The trading volume massively increased as compared to the average trading volume yesterday Let’s dig in to explore more of it.
Indaptus Therapeutics, Inc. is the pre-clinical stage biotech stock that develops anti-tumor and antiviral therapeutics to cure various diseases. Its lead product candidate is Decoy20 the GMP manufacturing of which has been successfully manufactured by Indaptus stock.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The Patent News: A reason behind rising INDP stock:
Indaptus stock recently announced the issuance of notice of allowance for claims related to its platform technology by the United States Patent and Trademark Office. The patent having the title “Methods of Treatment of Infections Using Bacteria” come up with protection for INDP’s platform technology. The company’s platform is aligned with the standard of care for the treatment of HBV and HIV infections.
The management is happy to get notice of the allowance for a strategic patent. Indaptus technology platform for viral infections will further get validation due to the growing patent estate. Single-agent therapeutics that the INDP platform has derived produce remarkable broader activity as compared to standard care of treatment in HBV and HIV.
Future Outcome of INDP stock:
The allowance notice has opened the doors for Indaptus Therapeutics to confidently pursue its technology in viral diseases. This event will play a major role in the future development of INDP stock in terms of both operational and financial. The expanding business of growing patient estate will bring positive outcomes for INDP stock.
INDP stock has captivated the attention of investors after the announcement of notice of allowance for a patent. The stock nearly tripled yesterday in response to the latest news. Its performance in terms of per-share price in 2021 is not so much satisfactory as it lost almost 26% year to date. In a nutshell, deep fundamental, as well as technical analysis, is necessary before adding this stock to the portfolio.